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Abstract
Background Many illnesses demonstrate seasonal and
geographic variations. Pharmacovigilance is unique among
public health surveillance systems in terms of the clinical
diversity of the events under surveillance. Since many
pharmacovigilance signal detection methodologies are
geared towards looking for increased frequency of spon-
taneous adverse drug event (ADE) reporting over variable
time frames, seasonality of ADEs may have implications
for signal detection.
Objective The aim of this study was to investigate whether a
set of illnesses that might be expected to display seasonality
in general, did so when spontaneously reported as ADEs.
Methods We performed our analysis with the publically
available US FDA Adverse Event Reporting System
(FAERS) data. We selected a convenience sample of
events possibly triggered by seasonal factors (hypothermia,
Raynaud’s phenomenon, photosensitivity reaction, heat
exhaustion, heat stroke, and sunburn) and events for which
previous literature experience suggests seasonality (anen-
cephaly and interstitial lung disease). Our statistical pro-
cedures can be explained in terms of a simple
physicogeometric setting: the unit circle divided into 6
(semiannual sinusoidal) or 12 (annual sinusoidal) arcs.
When reporting frequencies (weights) are more or less
evenly distributed across months, the center of mass of the
circle would not be significantly displaced from the origin
(0, 0). Distinct seasonal patterns will significantly displace
the center of mass of the circle.
Results Various patterns of seasonality were identified for
some, but not all, events and region–event pairs. USA
displayed the most instances of seasonality. Scandinavia
did not display seasonality for any events. Seasonality was
usually annual sinusoidal. Possible explanations for failure
to observe seasonality are briefly considered.
Conclusions Understanding seasonality of spontaneous
ADE reporting may have public health policy and research
implications and may mitigate false-positive and missed
true-positive pharmacovigilance signals. More systematic
study of seasonality of spontaneous ADE reporting, includ-
ing additional events with more or less biological rationale
for seasonality, is a logical extension of this analysis.
Key Points
Adverse events may display seasonal and geographic
reporting variations.
Awareness of these patterns may improve the
interpretation of outputs from signal detection
exercises.
Knowledge of adverse event seasonality may
provide opportunities for public health intervention.
1 Introduction
Various illnesses have been reported to display seasonal
variation. Some of these have obvious intuitive plausibility
(e.g., heat exhaustion and other temperature- or weather-
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related conditions, vector-borne conditions affected by
weather and light, events affected by seasonal behavior
including food consumption, travel, alcohol consumption,
and/or recreational activities). For others it might not be as
obvious, and for some no clear explanation is apparent
(e.g., Kawasaki disease [1], atrial fibrillation [2]).
A principal concern of pharmacovigilance is the ongo-
ing monitoring of spontaneous reports of illnesses for
which the reporter suspects a causal relationship with one
or more drugs, medical devices, or biologics. Pharma-
covigilance is rather unique as far as monitoring/surveil-
lance programs go by virtue of the extreme diversity of the
clinical and quantitative phenotypes of illnesses under
surveillance. Therefore, we were curious whether season-
ality of medical illnesses may extend into the reporting of
these illnesses as suspected adverse drug reactions. Such
patterns, if present, could have implications for both public
health policy and adverse event monitoring, specifically the
interpretation of potential pharmacovigilance signals based
on changes in spontaneous adverse event (AE) reporting
frequency. For example, some traditional approaches to
pharmacovigilance signal detection are based on detecting
increased AE reporting frequency. Depending on opera-
tional details, a seasonal increase in AE reporting could be
attributed to a drug. This may be especially true for new or
infrequently monitored drugs which may not have accu-
mulated a sufficient corpus of AE reports over time to
clearly demonstrate seasonality.
The objective of the current analysis is to investigate
whether various illnesses that are reported in the context of
a suspect adverse drug reaction display seasonal and/or
geographic variations. We analyze data from a number of
conditions that can be partitioned into three classes. First
we consider the ones that may be triggered by cold
weather; next those that are associated with warm weather;
and then those adverse drug events (ADEs) for which
previous literature or experience suggest seasonality, even




The FDA maintains the Adverse Event Reporting System
(FAERS), a database that contains information related to
post-marketing medication error reports and safety
surveillance as well as individually reported adverse events
submitted by healthcare providers and consumers them-
selves, which may include patients, family members, or
lawyers. The FAERS is evaluated and overseen by clinical
reviewers in the Center for Drug Evaluation and Research
(CDER) and the Center for Biologics Evaluation and
Research (CBER). The CDER and CBER monitor these
reports for any potential safety concerns after the drug is
initially approved by the FDA [3]. Adverse events are
recorded in FAERS using the Medical Dictionary for
Regulatory Affairs (MedDRA Version 15.0) Preferred
Terms (PTs) [4, 5]. PTs are intended to represent a single
medical concept and linked with broader Higher-Level
Terms (HLTs), Higher-Level Group Terms (HLGTs),
System Organ Classes (SOCs), and narrower groupings
(reported terms) in a hierarchical structure.
Gathered from the public release of the FAERS database,
the data are for the period 1997–2011, all years inclusively.
Separately for each region and each condition, the data were
pooled into twelve monthly totals. The regions are Japan,
Scandinavia, and the US. Our selection of regions was based
on the fact that these areas have well developed pharma-
covigilance systems and, while a convenience sample, these
regions were otherwise sufficiently diverse to allow explo-
ration of seasonal and geographic variation.
2.2 Events Selected
For purposes of this pilot study, we performed a 2-step con-
venience sample. First we selected a convenience sample of
medical events that may be triggered by seasonal factors. Then
we identified the closest matching MedDRA PTs by manual
inspection of MedDRA. For cold weather, we consider the
PTs hypothermia and Raynaud’s phenomenon. In the cate-
gory of events that are associated with warm weather, we
study the PTs photosensitivity reaction, heat exhaustion, heat
stroke, and sunburn. In the last set—those ADEs for which
previous literature or experience suggest seasonality, even if
there is not an obvious intuitive justification or expectation of
seasonality—we consider the PTs anencephaly and interstitial
lung disease; for instance, in the studies by Edwards and
Marrero [6–8], anencephaly was found to exhibit seasonal
variation, and Olson et al. [9] found that mortality from pul-
monary fibrosis is greatest in the winter.
2.3 Statistical Analyses
Statistical tests of seasonality include v2 and harmonic
analysis in which the monthly pattern of observations is
approximated using sine and cosine functions. We use a form
of harmonic analysis. The original sources for the specific
form of harmonic analysis are Marrero [7] for the single-
group case and Marrero [10] for the multigroup case. We
chose this method because a simulation study [7] shows that
it performs better than another form of harmonic analysis
known as Edwards’s test [6] and the chi-square test. In par-
ticular, the study [7] reveals that our method has the correct
type I error rate for sample sizes as low as 15. Edwards’s test
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has an unacceptably high type I error rate with small sample
sizes. Moreover, in Marrero [7] it is also shown that our
procedure is often 25 % more powerful than the chi-square
test, and such gain can be as high as 40 %.
In the medical sciences, three commonly seen seasonal
patterns are annual sinusoidal, semiannual sinusoidal, and
annual unimodal. Our method is adequate and can produce
statistically significant results for all three of these patterns.
As examples, our procedure has been successfully used to
demonstrate seasonality for diabetes mellitus diagnoses
[11], whose annual sinusoidal pattern is shown in Fig. 1;
Crohn’s disease onset of symptoms [11], whose semiannual
sinusoidal pattern is shown in Fig. 2; and the cases of
extrahepatic biliary atresia (EHBA) [12], whose rectangu-
lar annual unimodal pattern is shown in Fig. 3. Remark-
ably, the EHBA dataset is a concrete example of the
method’s high power: a statistically significant result was
obtained with just 30 observations.
We used the number of spontaneous reports per month
as our primary outcome metric. The null hypothesis is that
of uniformity: the probability that an event occurs is the
same for all the months. The alternative hypothesis is
unrestricted (i.e., it is unnecessary to specify the shape of
the deviation from uniformity) and this is an advantage of
these methods; however, in practice, investigators specify a
priori a pattern for the alternative hypothesis.
3 Results
Of eight events examined, four didn’t have enough data for
the multigroup procedure, which produced statistically
significant results for three of the other four events. Of 24
region–event pairs, seven displayed seasonal reporting
patterns for the single-group procedure (ten not performed
due to limited data). The detailed findings are now
presented.
3.1 Hypothermia
Separately by region, the data for Japan, Scandinavia, and
the US were pooled into twelve monthly totals that are
shown in Table 1.
First we applied the multigroup procedure [10] to







































Fig. 3 Extrahepatic biliary atresia: data and model
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each region, the null hypothesis was that of uniformity, and
the alternative hypothesis was that the data follow an
annual sinusoidal pattern with peak in winter and trough in
summer. The result was statistically significant
(p = 0.000028). As is evident from Fig. 4, the three
regions appear to follow different patterns. Further analy-
ses were, therefore, conducted separately by region, fol-
lowing the method developed by Marrero [7], and using the
same hypotheses.
The data from Japan produced a statistically significant
result (p = 0.0000011). However, the data from Scandi-
navia were not statistically significant (p = 0.6492), and
neither were the data from the US (p = 0.2907). This
agrees with what is shown in Fig. 4, where we see that the
descriptive annual sinusoidal models for Scandinavia and
the US are nearly flat, yet there is some oscillation in the
US model, but not enough to be significant, and, moreover,
the model does not fit the data well. For Japan, however, an
annual sinusoidal model fits the data well.
3.2 Raynaud’s Phenomenon
Separately by region, the data from Japan, Scandinavia,
and the US were pooled into twelve monthly totals that are
shown in Table 1.
We applied the multigroup procedure [10] to simulta-
neously test for seasonality in all three regions. For each
region, the null hypothesis was that of uniformity. The
alternative hypothesis was that the data follow an annual
sinusoidal pattern with peak in winter and trough in sum-
mer. The result was not statistically significant
(p = 0.0921).
Table 1 FAERS data
(1997–2011) monthly totals for
events possibly triggered by
seasonal factors or for which
previous literature experience
suggests seasonality, by region
Region Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Hypothermia
Japan 16 29 20 13 8 9 6 11 6 7 7 15
Scandinavia 8 4 4 5 4 1 5 6 3 4 3 5
USA 30 41 34 38 32 27 41 22 51 33 38 47
Raynaud’s phenomenon
Japan 2 5 6 0 1 1 0 2 2 1 3 2
Scandinavia 0 1 1 5 4 2 1 3 5 3 2 2
USA 29 25 42 31 18 32 25 30 26 33 36 36
Photosensitivity reaction
Japan 3 2 8 7 14 13 11 6 12 7 4 4
Scandinavia 1 4 4 5 4 8 4 7 4 1 3 5
USA 82 140 99 70 65 102 126 152 119 91 116 167
Heat exhaustion
Japan 0 0 0 0 0 1 0 1 0 3 0 0
Scandinavia 0 0 0 0 0 0 1 0 0 0 0 0
USA 3 3 11 2 8 13 15 19 14 5 13 5
Heat stroke
Japan 0 0 0 0 0 0 2 0 4 1 2 0
Scandinavia 0 0 0 0 1 0 0 0 0 0 0 0
USA 6 2 5 3 8 19 17 18 21 9 6 11
Sunburn
Japan 0 0 0 0 0 1 0 0 0 0 1 0
Scandinavia 0 0 0 1 1 1 0 0 0 0 0 0
USA 27 31 27 28 28 49 53 84 47 40 42 83
Anencephaly
Japan 1 1 1 0 0 0 1 1 0 0 1 0
Scandinavia 0 1 1 0 0 0 1 0 2 0 1 1
USA 3 4 1 1 4 1 2 4 6 2 3 5
Interstitial lung disease
Japan 197 242 290 265 246 321 268 284 279 268 280 350
Scandinavia 7 9 7 4 4 3 14 5 3 6 6 4
USA 70 62 90 67 74 89 107 95 90 110 98 144
FAERS US FDA Adverse Event Reporting System
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The Japan data contributed the most (55 %) to the
multigroup test-statistic value, and the contributions from
the other regions were about equal. For that reason, we
decided to test the Japan data alone for annual seasonality;
the result was close to being significant (p = 0.0505). In
Fig. 5, we note that the data from the US show variability
about the sinusoidal model, especially earlier in the year,
and the Scandinavia data are essentially flat, which helps to
explain the nonsignificance for these two regions. For
Japan, the data appear reasonably faithful to the sinusoidal
model, and that agrees with the low p value. Probably one
the most often cited limitations of data from a spontaneous
reporting system (SRS), underreporting may also con-
tribute to the nonsignificance.
3.3 Photosensitivity Reaction
Separately by region, the data from Japan, Scandinavia,
and the US were pooled into twelve monthly totals that are
shown in Table 1.
First we applied the multigroup procedure [10] to
simultaneously test for seasonality in all three regions. For
each region, the null hypothesis was that of uniformity. The
alternative hypothesis for Japan and Scandinavia was that
the data follow an annual sinusoidal pattern with peak in
summer and trough in winter, and for the US that the data
follow a semiannual sinusoidal pattern with peaks in winter
and summer, and troughs in the other seasons. The result
was statistically significant (p = 0.000000007). As is evi-
dent from Fig. 6, the three regions appear to follow dif-
ferent patterns. Further analyses were, therefore, conducted
separately by region, following the method developed by
Marrero [7], and using the same hypotheses.
The data from Japan produced a statistically significant
result (p = 0.0003), and so did the data from the US
(p = 0.00000058). However, the data from Scandinavia
were not statistically significant (p = 0.1372). This agrees
with what is shown in Fig. 6, where we note the following.
For Japan, an annual sinusoidal model fits the data well.
For the US, a semiannual sinusoidal model is adequate, but
some data points do not conform well to the model. The
data for Scandinavia are nearly constant.Fig. 4 Hypothermia: FAERS data (1997–2011) and models. FAERS
US FDA Adverse Event Reporting System
Fig. 5 Raynaud’s phenomenon: FAERS data (1997–2011) and
models. FAERS US FDA Adverse Event Reporting System
Fig. 6 Photosensitivity reaction: FAERS data (1997–2011) and
models. FAERS US FDA Adverse Event Reporting System
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3.4 Heat Exhaustion
We only considered the data for the US because there were
too few observations for the other two regions: five
observations for Japan and one observation for Scandi-
navia. The data for the US were pooled into twelve
monthly totals that are shown in Table 1.
We applied the single-group procedure [7] to test the US
data for seasonality. The null hypothesis was that of uni-
formity. The alternative hypothesis was that the data follow
an annual sinusoidal pattern with peak in summer and
trough in winter. The result was statistically significant
(p = 0.0000194). This agrees with what is shown in Fig. 7,
where we see that the descriptive annual sinusoidal model
for the US shows annual sinusoidal variation, with a peak
in mid August and trough in mid February; the model fits
the data well.
3.5 Heat Stroke
We only considered the data for the US because there were
too few observations for the other two regions: nine
observations for Japan and one observation for Scandi-
navia. The data for the US were pooled into twelve
monthly totals that are shown in Table 1.
We applied the single-group procedure [7] to test the US
data for seasonality. The null hypothesis was that of uni-
formity. The alternative hypothesis was that the data follow
an annual sinusoidal pattern with peak in summer and
trough in winter. The result was statistically significant
(p = 0.000000033). This agrees with what is shown in
Fig. 8, where we see that the descriptive annual sinusoidal
model for the US shows annual sinusoidal variation, with a
peak in mid August and trough in mid February; the model
fits the data well.
3.6 Sunburn
We only considered the data for the US because there were
too few observations for the other two regions: two
observations for Japan and three observations for Scandi-
navia. The data for the US were pooled into twelve
monthly totals that are shown in Table 1.
We applied the single-group procedure [7] to test the US
data for seasonality. The null hypothesis was that of uni-
formity. The alternative hypothesis was that the data follow
an annual sinusoidal pattern with peak in summer and
trough in winter. The result was statistically significant
(p = 0.000000033). It is clear from Fig. 9 that an annual
sinusoidal model does not fit the data well. From January to
July, the data appear to follow an annual sinusoidal pattern
with low points in January through May, and then increases
as the weather gets warmer in June and July. However, the
data from August through December are best described by
a U-shaped model that has maxima in August and
December, and a nadir in October.
3.7 Anencephaly
We only considered the data for the US because there were
too few observations for the other two regions: six obser-
vations for Japan and seven observations for Scandinavia.
The data for the US were pooled into twelve monthly totals
that are shown in Table 1.
Fig. 7 Heat exhaustion: FAERS data (1997–2011) and model.
FAERS US FDA Adverse Event Reporting System
Fig. 8 Heat stroke: FAERS data (1997–2011) and model. FAERS US
FDA Adverse Event Reporting System
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We applied the single-group procedure [7] to test the US
data for seasonality. The null hypothesis was that of uni-
formity. The alternative hypothesis was that the data follow
an annual sinusoidal pattern with peak in winter and trough
in summer. The result was not statistically significant
(p = 0.2952). In Fig. 10 we see that both the data and the
corresponding descriptive model are essentially flat.
3.8 Interstitial Lung Disease
Separately by region, the data for Japan, Scandinavia, and
the US were pooled into twelve monthly totals that are
shown in Table 1.
First we applied the multigroup procedure [10] to
simultaneously test for seasonality in all three regions. For
each region, the null hypothesis was that of uniformity, and
the alternative hypothesis was that the data follow an
annual sinusoidal pattern with peak in winter and trough in
summer. The result was statistically significant
(p = 0.000269). As is evident from Fig. 11, the three
regions appear to follow different patterns. Further analy-
ses were, therefore, conducted separately by region, fol-
lowing the method developed by Marrero [7], and using the
same hypotheses.
The data from the US produced a statistically significant
result (p = 0.000024). However, the data from Japan were
not statistically significant (p = 0.1197), and so were the
data from Scandinavia (p = 0.9777).
The individual p values agree with what is shown in
Fig. 11, where we see that the descriptive annual sinusoidal
model for the US fits the data well, with maximum
spontaneous reporting frequency in mid October and
minimum spontaneous reporting frequency in mid April.
The data from Japan generally appear to follow an annual
sinusoidal model with higher data on average than that of
the US, but there are three aberrant observations—January,
June, and December—that do not conform well to the
model; this lack of fit, of course, helps to increase the
p value. The data from Scandinavia are essentially flat.
Our findings by region are summarized in Table 2.
Fig. 9 Sunburn: FAERS data (1997–2011) and model. FAERS US
FDA Adverse Event Reporting System
Fig. 10 Anencephaly: FAERS data (1997–2011) and model. FAERS
US FDA Adverse Event Reporting System
Fig. 11 Interstitial lung disease: FAERS data (1997–2011) and
models. FAERS US FDA Adverse Event Reporting System
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4 Discussion
We have found that the spontaneous reporting of selected
adverse drug events display seasonal/cyclic variation and
that these variations occur more or less in relation to
geographic locale. Of eight events examined, four didn’t
have enough data for multigroup procedure, which returned
statistically significant results for three of the other four
events. Of 24 region–event pairs, seven displayed seasonal
reporting patterns and ten were not analyzed because of
limited data. Various patterns of seasonality were identified
for some, but not all, events and region–event pairs. When
seasonality was observed, it was usually annual sinusoidal.
The US displayed the most instances of seasonality.
Scandinavia did not display seasonality for any events. One
or more heat-/light-related events displayed seasonality in
both Japan and the US, while cold-related events displayed
seasonality only in Japan. Of our third class of events,
those for which literature suggests seasonality despite no
obvious intuitive justification, only interstitial lung disease
displayed seasonality, and it was only in the US. For the
US, multiple clinically similar heat-/light-related events
displayed seasonality. Other groups of events did not show
similarly consistent reporting patterns.
We can only speculate about why some events and
region–event pairs did not display expected patterns (based
on the biological plausibility arguments or actual data for
the events when not linked to drug administration). Possi-
ble hypotheses to explain these instances include geo-
graphic differentials in inter-seasonal temperature
gradients (in geographic regions otherwise at comparable
latitudes), differential population mobility/travel, genetic
adaptation to environment, public health support infras-
tructure, cultural norms, and the intensity of surveillance. It
is likely that for some events, univariate model of sea-
sonality is an over-simplification. For example, intuition
suggests increased photosensitivity during warmer seasons
when people are outdoors and the days are longer. Yet
other factors, such as cloud cover, may confound this
relationship, and would not be directly accommodated in
our models [13]. Additionally, numerous factors influence
spontaneous reporting, and these may distort the link
between actual occurrence and reporting.
Our findings, while intrinsically interesting, may also
potentially have practical implications for pharmacovigi-
lance and public health policy. First, if it is verified that some
of the geographic gradients in overall reporting and/or sea-
sonality that we observed with spontaneous reporting are in
part a function of public health education as, for example, we
speculated for the heat exhaustion and heat stroke events,
then this suggests possibilities for public health interven-
tions. Second, in the domain of pharmacovigilance,
surveillance for potential signals of novel adverse effects of
drugs, devices, and biologicals may entail monitoring
spontaneous reporting frequencies or various functions of
these frequencies. When such potential signals are identified
based on relatively short monitoring time windows/com-
parison periods, the possibility of a false-positive signal due
to seasonality or other cyclic variation may be considered
and evaluated prior to full signal evaluation. This could help
focus finite pharmacovigilance resources by reducing time
and energy spent on false-positive findings. This may be
especially pertinent for adverse events that do not have an
obvious intuitive rationale to expect seasonality/cyclic
variation. It is even theoretically possible that seasonal
variation could obscure a signal (i.e., a false negative).
There are limitations to our analysis. The enormous
limitations of SRS databases, which are well documented
and which have been alluded to in one form or another in
this paper, prevent making any inferences about the
underlying population risks of these events or the temporal
variation of these risks. When comparing overall reporting
between international regions, we note that the FDA cri-
teria for inclusion of spontaneous reports submitted to them
Table 2 Results summary of
the seasonality analysis
Nonsignificant Annual sinusoidal Semiannual sinusoidal
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become a sort of filter, so the FAERS database may rep-
resent a biased sample with regards to international reports;
the bias may be in part related to the novelty and seri-
ousness of the event. A corollary of these limitations is that
many of our proposed explanations remain hypothetical.
We examined individual MedDRA PTs. More detailed
future analyses might fruitfully use higher levels of the
MedDRA hierarchy, or pool conceptually related individ-
ual PTs to increase effective sample size. This might allow
analysis for geographic area–event pairs for which there
were not enough data available for this first-pass analysis.
It would also provide a check on the robustness of findings,
since one would expect that events that are sufficiently
related to share a common pathophysiological basis should
display similar seasonal or cyclic variation. We also did not
stratify by drugs, analyzing marginal event reporting fre-
quencies. Specific drugs or groups of drugs might be sub-
jected to more or less seasonal or cyclic variation, and
strategies for increasing power may facilitate such analysis.
We also note the possibility of culture reporting differ-
ences/biases; and, of course, there is the influence that
unusual extreme weather changes can have in the reporting
patterns from one year to the next. We analyzed events for
which seasonality in reporting makes sense.
Studying additional events, including those with less
apparent logical connection to seasonality, may mean the
discovery of similar yet unexpected reporting patterns that
may refine pharmacovigilance signal detection, evaluation,
and management. The same can be said of studying addi-
tional geographic regions. We analyze data from regions that
are all in the Northern Hemisphere. But our method can be
used to extend the analysis to include data from different
hemispheres. For example, if we were analyzing data from
the US and Australia, then all we need to do is shift one of the
monthly datasets by 6 months. Thus, for example, the
ordered list for the US could be, as usual, (Jan, Feb, Mar,…,
Dec) and that for Australia would then be (Jul, Aug, Sep,…,
Jun). Then the corresponding seasons would match: summer
in the US (Jun, Jul, Aug) would correspond to summer in
Australia (Dec, Jan, Feb); autumn in the US (Sep, Oct, Nov)
would match autumn in Australia (Mar, Apr, May), etc.
5 Conclusions
Our preliminary study of a limited convenience sample
suggests that performing quantitative analysis to detect
seasonality of spontaneous adverse event reporting has the
potential to usefully increase situational awareness in
pharmacovigilance. As is often the case, the interwoven
complexity of drug use and reporting behavior, and qual-
itative and quantitative limitations inherent in SRS data,
may conspire against obtaining clear and consistent results
in all cases. A natural extension of this work is using sets of
test events that more fully accommodate the quantitative
and phenotypic diversity of SRS data, as well as the
structure of the dictionaries used to memorialize the data.
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